Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Giant Biogene Holding Co., Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce that Shaanxi Giant Biotechnology Co., Ltd., a wholly-owned subsidiary of the Company, has received the Medical Device Registration Certificate of the People's Republic of China (Registration Certificate No.: Guo Xie Zhu Zhun 20253132049) issued by China National Medical Products Administration in respect of the product titled Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers (the "**Product**") today. With recombinant collagen as its main ingredient, the Product is intended for filling facial dermal tissue to correct frontal dynamic wrinkles, including glabellar lines, forehead lines and crow's feet.

This Product is China's first recombinant type I native-sequence collagen facial injectable product, officially approved through the joint review by the Medical Device Evaluation and Pharmaceutical Evaluation divisions. The approval of this product demonstrates the Company's core competitiveness in technology R&D and industrialization, further enriches the product portfolio of the Company, and will bring new opportunities for the Company's business development in the skin rejuvenation market. In the future, the Company will gradually carry out the market launch and promotion efforts of this product in accordance with its business plan. It will fully leverage its existing products, brands, and channels to provide consumers with more diversified experiences, continuously solidifying the Company's leading position in the health and beauty sector.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi'an, the PRC, 23 October 2025

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.